Dynamic Technology Lab Private Ltd Acquires New Position in Natera, Inc. $NTRA

Dynamic Technology Lab Private Ltd acquired a new stake in Natera, Inc. (NASDAQ:NTRA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 9,894 shares of the medical research company’s stock, valued at approximately $1,593,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 44.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after buying an additional 3,263,822 shares during the period. Norges Bank purchased a new stake in shares of Natera in the second quarter valued at approximately $277,749,000. AQR Capital Management LLC grew its holdings in Natera by 44.6% during the second quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company’s stock worth $291,717,000 after acquiring an additional 532,769 shares during the period. Franklin Resources Inc. raised its position in Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company’s stock worth $327,346,000 after acquiring an additional 330,696 shares in the last quarter. Finally, Holocene Advisors LP raised its position in Natera by 118.3% in the second quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company’s stock worth $96,774,000 after acquiring an additional 310,452 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on NTRA. BTIG Research boosted their target price on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Citigroup assumed coverage on shares of Natera in a report on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price target for the company. JPMorgan Chase & Co. raised their price objective on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Robert W. Baird boosted their price objective on shares of Natera from $239.00 to $257.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Finally, Barclays upped their target price on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.47.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 23,205 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the sale, the insider directly owned 144,992 shares in the company, valued at $34,035,422.08. This represents a 13.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 85,299 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the sale, the chief executive officer directly owned 127,881 shares in the company, valued at approximately $29,504,704.32. The trade was a 40.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 363,303 shares of company stock valued at $84,523,079. Company insiders own 5.63% of the company’s stock.

Natera Stock Up 0.5%

Shares of NTRA stock opened at $198.13 on Friday. The business has a fifty day simple moving average of $223.11 and a 200-day simple moving average of $205.28. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The stock has a market cap of $28.08 billion, a P/E ratio of -129.50 and a beta of 1.65.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same quarter in the prior year, the firm earned ($0.41) earnings per share. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.